Biotechnology
Exyte Receives Micron's Outstanding Supplier Performance Award in Supplier Diversity
STUTTGART, Germany, Nov. 26, 2024 /PRNewswire/ -- Exyte, a global leader in the design, engineering, and delivery of high-tech facilities, was presented with the Outstanding Supplier Performance Award in Supplier Diversity at the Micron Supplier Day 2024. The event, held inSan Francisco, CA, USA,...
2024-11-26 20:19
2221
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
SINGAPORE, Nov. 26, 2024 /PRNewswire/ -- QDX proudly announces that the team led by its co-founder, Associate ProfessorGiuseppe Barca, has been honoured with the 2024 ACM Gordon Bell Prize, often referred to as the "Nobel Prize of high-performance computing." This accolade recognizes their ground...
2024-11-26 18:49
9631
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
* Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC. * Updated results of elacestrant in combination with abemaciclib show favorable efficacy regardless of theESR1 mutation status, with a manageable and predictable safet...
2024-11-26 17:16
3719
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
ROCKVILLE, Md. and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed M...
2024-11-25 08:37
4612
Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024
SAN FRANCISCO and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-11-25 08:30
4590
ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection
SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infec...
2024-11-25 08:18
3837
SCG Cell Therapy Presents Promising Phase 1 Data for a Novel HBV-Specific TCR-T Therapy (SCG101) at the AASLD Liver Meeting 2024
SINGAPORE, Nov. 25, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associated cancers, announced late-breaking data from its Phase 1 trial of SCG101, a first-in-class autolog...
2024-11-25 08:01
2258
International Genomics Conference (ICG-19) Opens at BGI Group HQ in Shenzhen
SHENZHEN, China, Nov. 22, 2024 /PRNewswire/ -- The 19th Annual Meeting of the International Conference on Genomics (ICG-19) officially opened at BGI Group's Global Headquarters inShenzhen. This annual event brings together over 100 leaders in the field of genomics from the U.S., UK,Denmark, Austr...
2024-11-22 21:57
4934
FDA Granted Orphan Drug Designation of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs, for Treatment of Neuroendocrine Cancer
NANJING, China, Nov. 22, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by the company with global intellectual property rights for the treatment of neuroendo...
2024-11-22 16:00
8528
Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity
SHANGHAI, Nov. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that data on its critical-care, anti...
2024-11-22 12:14
3647
Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology
ROCKVILLE, Md. and SUZHOU, China, Nov. 22, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, announced today that findings from a ph...
2024-11-22 10:27
3581
SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024
Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland, Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IM...
2024-11-21 18:30
2108
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including$420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead...
2024-11-21 06:00
2901
GBI Biomanufacturing Expands Capabilities with Automated Aseptic Fill-Finish for Drug Products
PLANTATION, Fla., Nov. 21, 2024 /PRNewswire/ -- GBI Biomanufacturing (GBI), one of the world's longest serving contract development and manufacturing organizations (CDMO), is pleased to announce the expansion of its Drug Product (DP)services, to include automated sterile fill and finish capabilit...
2024-11-21 01:00
1854
Samsung Biologics signs manufacturing deal with European pharmaceutical company
* The company will provide manufacturing services through 2031 in deals worth overUSD 668 million * Samsung Biologics' cumulative contract value for 2024 surpasses USD 4 billion with latest deals INCHEON, South Korea, Nov. 20, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global ...
2024-11-20 07:23
2856
Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinson's Research Through Development of Next Generation Biomarker Assays
FREMONT, Calif., Nov. 19, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to accelerate biomarker disco...
2024-11-19 22:12
2231
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA
48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Data from multiple combination studies sponsored by the Company and its partner continue to suppor...
2024-11-19 19:30
4004
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
MELBOURNE, Australia, Nov. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nucl...
2024-11-19 06:24
3061
VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
SHANGHAI and BOSTON, Nov. 18, 2024 /PRNewswire/ -- VelaVigo Cayman Limited (VelaVigo), a biotech company focusing on discovery and development of multi-specific antibodies and antibody-drug conjugates (ADC), today announced it has entered into an agreement with Avenzo Therapeutics, Inc. (Avenzo)...
2024-11-18 21:01
2415
New Report from Clarivate and Healthcare Executive Explores Mainland China's Biopharma Revolution and Increasing Global Influence
New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON, Nov. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership withHealthcare Executi...
2024-11-18 16:00
2264
Week's Top Stories
Most Reposted
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 300 media titles]
2026-06-04 23:55
Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 292 media titles]
2026-06-05 19:08
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 292 media titles]
2026-06-05 15:00FPT and NVIDIA Collaborate to Release the Nemotron Personas Vietnam Datasets
[Picked up by 276 media titles]
2026-06-05 17:34
Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00Most Read
WePlay Korea's 4th Anniversary Celebration Kicks Off, Joining Hands with "Hello Panda-哈啰潘达" to Create Fu Bao Themed Space Decorations
2026-06-01 12:00
7980
Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC)
2026-06-05 21:05
7508
CERAVE CELEBRATES OVER 100 AWARD-WINNING CONTENT CREATORS FROM 22 COUNTRIES FOR THE FIRST EVER GLOBAL CERAWARDS
2026-06-05 20:58
7018
